Perioperative medicine & outcomes
Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial
Authors' conclusion
Among patients undergoing liver resection for a cancer-related indication, tranexamic acid did not reduce bleeding or blood transfusion but increased perioperative complications.
Study context
- Population
- Patients undergoing liver resection for a cancer-related indication, 10 sites in Canada and 1 in the US1,245 in primary analysis
- Participants
- 1,384 patients
- Comparison
- TXA vs placebo
- Tranexamic acidn = 619
- Placebon = 626reference
- Primary endpoint
- Receipt of RBC transfusion
- Follow-up
- Within 7 days of surgery
Methodological detailsmulticentre, blinded, placebo-controlled, December 1, 2014, to November 8, 2022, 90-day follow-up
- Multicentre
- Blinded
- Placebo-controlled
- December 1, 2014, to November 8, 2022
- 90-day follow-up
Primary result
As reported in the abstract
Each group vs placeboOdds ratio (95% CI)P value
Tranexamic acid
1.15(0.84–1.56)
P = 0.38Each group vs placeboAbsolute difference (95% CI)
Tranexamic acid
2%(−2% to 6%)
Further findings
Measured intraoperative blood loss
P = 0.75
Total estimated blood loss · over 7 days
P = 0.38
Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| ComplicationsSignificantly more with TXA | 1.28 (1.02–1.60) | P = 0.03 | |
| VTE | 1.68 (0.95–3.07) | P = 0.08 | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial. JAMA. Published 1 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →